Literature DB >> 28386647

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.

Arezou Sayad1, Soudeh Ghafouri-Fard1, Mir Davood Omrani1,2, Rezvan Noroozi1, Mohammad Taheri3,4,5.   

Abstract

Multiple sclerosis (MS) is a heterogeneous immune-related demyelinating disorder of central nervous system with several genetic and environmental factors contributing in its pathogenesis or patients' response to therapies. Myxovirus resistance protein A (MxA) is among the genes which are induced by IFNβ and are involved in the MS pathogenesis and/or response to IFNβ. In the present case-control study, we evaluated the association between three SNPs at nt -123 (A or C, rs17000900), nt -88 (G or T, rs2071430), and nt +20 (A or C, rs464138) and MS risk as well as treatment response in a population of Iranian MS patients including 146 IFNβ responders and 85 non-responders as well as 180 healthy controls. The AGA (-123, -88, +20) haplotype was more frequent in controls compared with MS cases (P = 0.038, OR (95% CI) = 1.77 (1.03-3.02)). Of particular note, the frequency of rs464138 AA genotype was significantly higher in responders compared with non-responders. However, the allele and genotype frequencies of other SNPs were not significantly different among patient subtypes or between patients and controls. Besides, we have demonstrated that CGC, ATA, and AGA (-123, -88, +20) haplotypes were significantly associated with IFNβ response in MS patients. As SNPs on MxA promoter region might participate in MS patients' response to IFNβ, prior patients genotyping may increase the rate of responsiveness and help in individualized selection of treatment options.

Entities:  

Keywords:  Multiple sclerosis; MxA; Polymorphism

Mesh:

Substances:

Year:  2017        PMID: 28386647     DOI: 10.1007/s10072-017-2935-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (-123 and -88) in vivo and in vitro.

Authors:  M Hijikata; S Mishiro; C Miyamoto; Y Furuichi; M Hashimoto; Y Ohta
Journal:  Intervirology       Date:  2001       Impact factor: 1.763

2.  Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome.

Authors:  Z Rahmani; J L Blouin; N Creau-Goldberg; P C Watkins; J F Mattei; M Poissonnier; M Prieur; Z Chettouh; A Nicole; A Aurias
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

3.  Does Down's syndrome protect against multiple sclerosis?

Authors:  Franz X Weilbach; Klaus V Toyka
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

4.  The distinctive contrast of multiple sclerosis epidemiology between Persians and Armenian minority community of Isfahan city, Iran.

Authors:  Masoud Etemadifar; Seyed-Mohammadamin Nourian; Mojtaba Akbari; Seyed-Hossein Abtahi; Parto Nasri; Mahboobeh Fereidan-Esfahani
Journal:  Neurol Sci       Date:  2015-01-11       Impact factor: 3.307

5.  Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.

Authors:  Bianca Weinstock-Guttman; Miriam Tamaño-Blanco; Kavitha Bhasi; Robert Zivadinov; Murali Ramanathan
Journal:  J Neuroimmunol       Date:  2006-11-27       Impact factor: 3.478

Review 6.  Evaluation of the impact of neutralizing antibodies on IFNβ response.

Authors:  Antonio Bertolotto
Journal:  Clin Chim Acta       Date:  2015-03-10       Impact factor: 3.786

Review 7.  Interferons, Mx genes, and resistance to influenza virus.

Authors:  M A Horisberger
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

8.  Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.

Authors:  Thomas Liggett; Anatoliy Melnikov; Shilpa Tilwalli; Qilong Yi; Haiyan Chen; Charles Replogle; Xuan Feng; Anthony Reder; Dusan Stefoski; Roumen Balabanov; Victor Levenson
Journal:  J Neurol Sci       Date:  2010-01-12       Impact factor: 3.181

9.  Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.

Authors:  Antonio Bertolotto; Marco Capobianco; Maria Pia Amato; Elisabetta Capello; Ruggero Capra; Diego Centonze; Maria Di Ioia; Antonio Gallo; Luigi Grimaldi; Luisa Imberti; Alessandra Lugaresi; Chiara Mancinelli; Maria Giovanna Marrosu; Lucia Moiola; Enrico Montanari; Silvia Romano; Luigina Musu; Damiano Paolicelli; Francesco Patti; Carlo Pozzilli; Silvia Rossi; Marco Salvetti; Gioachino Tedeschi; Maria Rosaria Tola; Maria Trojano; Maria Troiano; Mauro Zaffaroni; Simona Malucchi
Journal:  Neurol Sci       Date:  2013-12-29       Impact factor: 3.307

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  8 in total

1.  Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod.

Authors:  Mohammad Mahdi Eftekharian; Alireza Komaki; Mehrdokht Mazdeh; Shahram Arsang-Jang; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2019-03-21       Impact factor: 3.444

2.  Down-regulation of ERMN expression in relapsing remitting multiple sclerosis.

Authors:  Behnaz Salek Esfahani; Jalal Gharesouran; Soudeh Ghafouri-Fard; Shahrzad Talebian; Shahram Arsang-Jang; Mir Davood Omrani; Mohammad Taheri; Maryam Rezazadeh
Journal:  Metab Brain Dis       Date:  2019-05-23       Impact factor: 3.584

3.  Assessment of Protein Prenylation Pathway in Multiple Sclerosis Patients.

Authors:  Mohammad Taheri; Soudeh Ghafouri-Fard; Arezou Sayad; Shahram Arsang-Jang; Mehrdokht Mazdeh; Mehdi Toghi; Mir Davood Omrani
Journal:  J Mol Neurosci       Date:  2018-03-25       Impact factor: 3.444

4.  Expression analysis of long non-coding RNAs and their target genes in multiple sclerosis patients.

Authors:  Maziar Ganji; Arezou Sayad; Mir Davood Omrani; Shahram Arsang-Jang; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  Neurol Sci       Date:  2019-01-24       Impact factor: 3.307

5.  Expression Analysis of Long Non-coding RNAs in the Blood of Multiple Sclerosis Patients.

Authors:  Mohammad Mahdi Eftekharian; Soudeh Ghafouri-Fard; Mohammad Soudyab; Mir Davood Omrani; Mahnoosh Rahimi; Arezou Sayad; Alireza Komaki; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  J Mol Neurosci       Date:  2017-10-01       Impact factor: 3.444

6.  Association Study of ANRIL Genetic Variants and Multiple Sclerosis.

Authors:  Maryam Rezazadeh; Jalal Gharesouran; Mohsen Moradi; Rezvan Noroozi; Mir Davood Omrani; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2018-04-30       Impact factor: 3.444

Review 7.  Pharmacogenomics of Multiple Sclerosis: A Systematic Review.

Authors:  Keli Hočevar; Smiljana Ristić; Borut Peterlin
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

8.  The Growth Arrest-Specific Transcript 5 (GAS5) and Nuclear Receptor Subfamily 3 Group C Member 1 (NR3C1): Novel Markers Involved in Multiple Sclerosis.

Authors:  Jalal Gharesouran; Mohammad Taheri; Arezou Sayad; Soudeh Ghafouri-Fard; Mehrdokht Mazdeh; Mir Davood Omrani
Journal:  Int J Mol Cell Med       Date:  2018-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.